Preparation method of COL4A3 mutation animal model
The COL4A3 p.G799R point mutant mouse model was constructed through CRISPR/Cas9 technology, which solved the problem of lack of effective animal models, realized the research and drug development of renal diseases related to COL4A3 mutations, and provided an effective simulation model for clinical research.
Patent Information
- Application Number
- CN202411047923.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-25
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-12
AI Technical Summary
Currently, there is a lack of an effective COL4A3 p.G799R point mutation animal model, which limits the progress of pathogenic mechanisms of related renal diseases and the development of therapeutic drugs.
Homologous recombination was carried out using CRISPR/Cas9 technology to construct a mouse model of amino acid point mutation at position 799 of COL4A3 gene, Cas9 mRNA and gRNA were obtained through in vitro transcription, and homologous recombination vector was constructed through In-Fusion cloning, and microinjected to fertilization. In the egg, after multigenerational hybridization and genotype identification, COL4A3 p.G799R point mutant mice were finally obtained.
Animal models that simulate the progression of renal diseases related to human COL4A3 mutation were successfully established to study the pathogenesis of hereditary chronic kidney disease and screen therapeutic drugs. The renal function and pathological changes in model mice were similar to those of human patients, with clinical studies and drugs. The application value of development.
Smart Images

Figure CN118931965A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of animal models, in particular to a method for preparing a COL4A3 mutation animal model. Background Art
[0002] Chronic kidney disease (CKD) and end-stage renal disease (ESRD) seriously threaten people's lives and health, and cause great social and economic burdens. Genetic factors are an important cause of CKD, among which collagen type IV mutation (COL4As) has been identified as the most common cause of hereditary CKD. COL4Aα3 / α4 / α5 chain mutation can cause a variety of kidney diseases and extrarenal manifestations, and is an important cause of Alport syndrome (AS), thin basement membrane nephropathy (TBMN), and hereditary focal segmental sclerosis nephropathy (FSGS).
[0003] Among them, IV collagen α3 chain (COL4A3) is the main component of the glomerular basement membrane (GBM), which is mainly synthesized in renal podocytes and secreted into the extracellular matrix to build the GBM skeleton, while being renewed in podocytes to maintain the integrity of the glomerular filtration barrier function. In addition, IV collagen α3 chain is also expressed in the distal tubular basement membrane (TBM), alveolar basement membrane, eye and cochlear basement membrane.
[0004] In previous clinical family analysis and follow-up, we found that patients with IV collagen α3 chain (COL4A3) mutations had early kidney involvement, and some patients progressed to ESRD in middle age, suggesting that COL4A3 gene mutations have important research value. However, there is still a lack of effective animal models of COL4A3 mutations internationally for pathogenic mechanism research and therapeutic drug development.
[0005] Chinese patent document CN113981000A discloses a COL4A3 p.P408H gene point mutation mouse model and its construction method, application and kit, and Chinese patent document CN110878306A discloses gene mutants and their applications. However, there is no report on the preparation method of a COL4A3 p.G799R point mutation animal model. Summary of the invention
[0006] The purpose of the present invention is to provide a method for preparing a COL4A3 p.G799R point mutation animal model and its application.
[0007] In order to achieve the above object, the first aspect of the present invention provides a method for preparing a COL4A3 p.G799R point mutation animal model, comprising the following steps:
[0008] Step 1: Based on the 801st amino acid of human COL4A3 protein (pathogenic mutation site), the mutation site of mouse COL4A3 gene (ID: 145699100) was determined to be COL4A3 p.G799R (GGA>CGA); Cas9 mRNA and gRNA were obtained by in vitro transcription, and the target sequence of gRNA was shown in SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3 ( Figure 1 , Table 1); construct homologous recombination vector (donor vector) by In-Fusion cloning method ( Figure 2-Figure 3 ) (nucleotide sequence as shown in SEQ ID No.4); Cas9 mRNA, gRNA and donor vector were microinjected into fertilized eggs of C57BL / 6J mice to obtain F0 generation mice ( Figure 4-Figure 5 );
[0009] Table 1
[0010] gRNAs Sequence(5'-3') gRNA1 gCCAGGACAGCCTGGATCACC SEQ ID No.1 gRNA2 gCCTTTTGCTCCAGGTGATCC SEQ ID No.2 gRNA3 gCCTGGGGATCCTTTTGCTCC SEQ ID No.3 donor vector gCAGCCTGGATCACCTCGAGCAAAAGGATCCCCAG SEQ ID No.4
[0011] Step 2: Mouse genotype identification and model
[0012] The injected fertilized eggs were transplanted into pseudo-pregnant female mice, and the mice born around 20 days later were F0 generation mice. The genotypes were identified by PCR amplification and sequencing to obtain the target mice (COL4A3 gene 799 site mutation, referred to as COL4A3p.G799R point mutation mice). The COL4A3p.G799R point mutation mice with C57BL / 6 background were hybridized to 129S2 / Sv background renal disease susceptible mice.
[0013] Step 3: Identification of genetic phenotypes of homozygous mice
[0014] Table 2. Primer information for genotyping of COL4A3 p.G799R point mutation mice
[0015] Primer Sequence 5'-->3' Primer Type I ACCTCCTATCCTGAGACCACCTTC Forward SEQ ID No.5 II ATCTTTAACCCTGATCCTGGCAAT Reverse SEQ ID No.6
[0016] Table 3. PCR reaction system for mouse genotyping
[0017] Reaction Component Volume(μl) <![CDATA[ddH 2 The]]> 13.2 GXL PCR Buffer 2 2.5mM dNTP 2 Primer I (10 pmol / μl) 0.5 Primer II (10 pmol / μl) 0.5 GXL DNA Polymerase* 0.8 Genomic DNA 1 Total 20
[0018] *PrimeStar GXL (TaKaRa, Code No: R050A)
[0019] The reaction conditions are shown in Table 4:
[0020] Table 4. PCR reaction procedure for mouse genotyping
[0021] Step# Temperature(℃) Time Note 1 94 3min - 2 98 15sec - 3 61 15sec - 4 68 4min Repeat steps 2-4 for 35 cycles 5 68 5min - 6 12 - hold
[0022] Step 4: Obtaining F1 generation mice and identifying their genotypes
[0023] F0 positive mice (C57BL / 6 background) were mated with wild-type C57BL / 6J mice to obtain F1 mice, which were genotyped by PCR and sequencing;
[0024] Step 5: Screen the F2 progeny and obtain the homozygous mutant mice therein, which are the COL4A3 p.G799R point mutation animal model to be prepared in the present invention.
[0025] Step 6: Identification of mouse disease phenotypes.
[0026] In a second aspect of the present invention, there is provided use of the COL4A3 p.G799R point mutation animal model constructed by the method for preparing the COL4A3 p.G799R point mutation animal model as described above in screening therapeutic drugs for hereditary chronic kidney disease.
[0027] The third aspect of the present invention provides the use of the COL4A3 p.G799R point mutation animal model constructed by the preparation method of the COL4A3 p.G799R point mutation animal model as described above in studying the pathogenesis of hereditary chronic kidney disease.
[0028] The advantages of the present invention are:
[0029] 1. The present invention first discovered the pathogenic COL4A3 p.G801R point mutation site in a clinical hereditary nephropathy family through whole exome sequencing. Further, by comparing the mouse and human COL4A3 gene sequences, the present invention found that the 799th amino acid of the mouse COL4A3 gene was homologous to the 801 site of the human COL4A3 gene. The COL4A3 p.G799R point mutation mouse was constructed by homologous recombination using Crispr / Cas9 technology ( Figure 1-7 , Table 1-4).
[0030] 2. The present invention detected the renal function and urine albumin-creatinine ratio (ACR) of homozygous mice at 8, 24, and 40 weeks of age. Compared with wild-type mice, the ACR level of mutant mice at 24 weeks of age gradually increased and reached a significant level ( Figure 8 A), body weight was reduced compared with the wild-type group ( Figure 8 C). Serum creatinine (Scr) levels also showed a similar upward trend, with a significant increase observed in mutant mice at 40 weeks ( Figure 8 B) In terms of kidney tissue damage assessment, foot processes were found to disappear in mutant mice at 8 weeks of age ( Fig. 9C, 9E), the mutant mice showed irregular thinning and thickening of GBM at 24 weeks of age ( Fig. 9 C, 9D), glomerular capillary loop contraction and collapse ( Fig. 9 A, 9B). This is similar to the progression of renal disease in patients with IV collagen α3 chain (COL4A3) mutations, confirming that the clinical phenotype and pathological results of the model mice of the present invention can effectively simulate the natural progression of clinical diseases related to COL4A3 mutations and can be used for related clinical research and drug development. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 : Schematic diagram of mouse construction strategy.
[0032] Figure 2 : Homologous recombination vector plasmid map.
[0033] Figure 3 :Identification of homologous recombination plasmid by enzyme digestion.
[0034] Figure 4 :Construction of COL4A3 p.G799R homozygous mutant mice; Note: A) Comparison of mouse COL4A3 gene cDNA and human COL4A3 gene cDNA. B) Targeting strategy diagram of mouse COL4A3 gene 799 site using Crispr / Cas9 technology. C) COL4A3 p.G799R mutant mice on C57BL / 6 background were crossed into nephropathy-susceptible mice on 129S2 / Sv background.
[0035] Figure 5 : Genotype identification of COL4A3 p.G799R homozygous mutant mice.
[0036] Figure 6 : Electrophoresis of PCR identification of 5' homology arms and 3' homology arms of F1 generation mice. The PCR identification strategy and method are the same as those of F0 generation mice identification. The electrophoresis results of PCR identification of 5' and 3' homology arms of F1 generation mice are as follows: Figure 5 As shown. The positive mice identified by PCR are No. 10, 13, and 14; all were confirmed to be positive by sequencing. (Numbers: F1 generation mouse number; WT: wild type control; M: 1kb DNA ladder)
[0037] Figure 7 :Schematic diagram of sequencing verification of PCR products of F1 generation mice.
[0038] Figure 8:Changes in blood Scr, urine ACR, and body weight of COL4A3 p.G799R point mutation mice at different ages. Note: A) Change trend of urine ACR (mg / g) between mutant mice and wild-type mice at different ages. B) Change trend of blood Scr between mutant mice and wild-type mice at different ages. C) Comparison of body weight between mutant mice and wild-type mice at the same age. *p<0.05, **p<0.01, ***p<0.001, ns, no statistical difference. Urinary albumin creatinine ratio, ACR, urine albumin / urine creatinine. Serum creatinine, Scr, blood creatinine.
[0039] Fig. 9 :Renal pathology of COL4A3 p.G799R mutant mice. Note: A) PAS staining was used to evaluate the glomerular lesions in wild-type mice and mutant mice at 8 and 24 weeks of age. B) H&E staining was used to evaluate the tubular lesions in wild-type mice and mutant mice at 8 and 24 weeks of age (black arrows indicate vacuolar degeneration of tubular epithelium). ×400 times, Scale Bar = 20 μm. C) Electron microscopy was used to evaluate the degree of podocyte foot process fusion (black arrows indicate podocyte foot process fusion) and glomerular basement membrane lesions in wild-type mice and mutant mice at 8 and 24 weeks of age (GBM measurement values are marked in the figure). ×400 times, Scale Bar = 20 μm. D) Analysis of basement membrane thickness in mice at 8 and 24 weeks of age. E) Changes in foot process fusion in mice of each group. Wk: week, age. podocyte process, foot process. GBM: glomerular basement membrane, glomerular basement membrane. *p<0.05, ***p<0.001, NS, no statistical difference. DETAILED DESCRIPTION
[0040] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.
[0041] Example 1: Construction of COL4A3 p.G799R point mutation animal model
[0042] Step 1: Using CRISPR / Cas9 technology, by homologous recombination, a point mutation at amino acid position 799 of the mouse COL4A3 gene (ID: 145699100) was introduced, corresponding to amino acid position 801 of the human COL4A3 protein (pathogenic mutation site).
[0043] The process is as follows: Cas9 mRNA and gRNA ( Figure 1 , Table 1); construct homologous recombination vector (donor vector) by In-Fusion cloning method ( Figure 2-Figure 3 ). Cas9 mRNA, gRNA and donor vector were microinjected into fertilized eggs of C57BL / 6J mice to obtain F0 generation mice ( Figure 4-Figure 5 ). The F0 mice that were positive for PCR amplification and sequencing were mated with C57BL / 6J mice to obtain three positive F1 mice (Table 2-Table 4, Figure 6-Figure 7 ).
[0044] Table 1
[0045] gRNAs Sequence(5'-3') gRNA1 gCCAGGACAGCCTGGATCACC SEQ ID No.1 gRNA2 gCCTTTTGCTCCAGGTGATCC SEQ ID No.2 gRNA3 gCCTGGGGATCCTTTTGCTCC SEQ ID No.3 donor vector gCAGCCTGGATCACCTCGAGCAAAAGGATCCCCAG SEQ ID No.4
[0046] Step 2: Mouse genotype identification and model
[0047] The injected fertilized eggs were transplanted into pseudo-pregnant female mice, and the mice born around 20 days later were F0 generation mice. The genotypes were identified by PCR amplification and sequencing to obtain the target mice (COL4A3 gene 799 site mutation, referred to as COL4A3p.G799R point mutation mice). The COL4A3p.G799R point mutation mice with C57BL / 6 background were hybridized into 129S2 / Sv background renal disease susceptible mice.
[0048] Step 3: Method for identifying the genetic phenotype of homozygous mice
[0049] Table 2. Primer information for genotyping of COL4A3 p.G799R point mutation mice
[0050] Primer Sequence 5'-->3' Primer Type I ACCTCCTATCCTGAGACCACCTTC Forward SEQ ID No.5 II ATCTTTAACCCTGATCCTGGCAAT Reverse SEQ ID No.6
[0051] Table 3. PCR reaction system for mouse genotyping
[0052] Reaction Component Volume(μl) <![CDATA[ddH 2 The]]> 13.2 GXL PCR Buffer 2 2.5mM dNTP 2 Primer I (10 pmol / μl) 0.5 Primer II (10 pmol / μl) 0.5 GXL DNA Polymerase* 0.8 Genomic DNA 1 Total 20
[0053] *PrimeStar GXL (TaKaRa, Code No: R050A)
[0054] The reaction conditions are shown in Table 4:
[0055] Table 4. PCR reaction procedure for mouse genotyping
[0056] Step# Temperature(℃) Time Note 1 94 3min - 2 98 15sec - 3 61 15sec - 4 68 4min Repeat steps 2-4 for 35 cycles 5 68 5min - 6 12 - hold
[0057] Step 4: Obtaining F1 generation mice and identifying their genotypes
[0058] The F0 positive mice were mated with wild-type C57BL / 6J mice to obtain the F1 mice, and their genotypes were identified by PCR and sequencing.
[0059] Step 5: Identification of mouse disease phenotypes.
[0060] The present invention first discovered the pathogenic COL4A3p.G801R point mutation site in a clinical hereditary nephropathy family through whole exome sequencing. Further, by comparing the mouse and human COL4A3 gene sequences, we found that the 799th amino acid of the mouse COL4A3 gene was homologous to the 801 site of the human COL4A3 gene, and constructed a COL4A3p.G799R point mutation mouse using Crispr / Cas9 technology ( Figure 1-7 , Table 1-4).
[0061] Example 2: Identification of disease phenotypes in mice
[0062] 1. Experimental Materials and Methods
[0063] 1. Breeding of Wild-Type / COL4A3 p.G799R Homozygous Mutant Mice
[0064] Homozygous mutant mice and wild-type mice were raised in the SPF animal room of Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine or in the SPF breeding environment of Jiading Finok Company, with an ambient temperature of 20°C. The mice were ear-tagged around 3 weeks after birth.
[0065] 2. Collection of Mouse Specimens
[0066] At 8, 16, 24, and 40 weeks of age, random urine was collected from mice through metabolic cages, and then stored at -80°C. Venous blood was obtained from mice by collecting blood from the medial canthus vein. After the venous blood was allowed to stand at room temperature for 2 hours, it was centrifuged at 3500rpm for 15 minutes to collect the supernatant, which was then stored at -80°C. The mouse abdominal cavity was opened to expose the kidneys, and the mouse chest cavity was opened to expose the mouse heart for cardiac perfusion. The kidneys of the mice were removed, the renal capsule was removed, and the kidneys were cut in half along the long axis of the mouse kidneys. Half of the kidneys were placed in 4% paraformaldehyde for fixation for 24 hours, and then tissue embedding, paraffin sectioning, PAS, H&E, Masson trichrome, and immunohistochemical staining were performed. Tissues of about 1 mm3 in size from the upper and lower poles of the mouse kidney were taken and stored in electron microscope fixative and sent to the electron microscope room of the School of Basic Medicine, School of Medicine, Shanghai Jiao Tong University for embedding. Some tissues were embedded in OCT fixative and quickly frozen in a -80°C refrigerator. The renal cortex of the remaining renal tissues was removed in preparation for subsequent Western Blot and RT-qPCR experiments.
[0067] 3. Mouse RNA Extraction
[0068] First, precool the high-speed centrifuge to 4°C.
[0069] Prepare 75% ethanol (1 volume of DEPC water + 3 volumes of analytical grade anhydrous ethanol) and place on ice.
[0070] Mouse renal cortical tissue frozen in liquid nitrogen was obtained, 1 ml of Trizol was added for every 200 mg of tissue, 1 smallest white magnetic bead + 1 large white magnetic bead were placed in each tube, and the tissue was ground using a tissue homogenizer at 60 Hz for 20 s twice (until it becomes a homogenate with no visible solid tissue), and then placed on ice for 30 min.
[0071] Collect the tissue lysate into RNAse free EP tubes (this step can be stored at -80°C).
[0072] Add 0.2 ml of chloroform (trichloromethane), shake vigorously for 15 seconds, shake for 1 second and invert once, and let stand at room temperature for 10 minutes.
[0073] Centrifuge at 4℃*12,000rpm*15min, and the tube will be divided into three layers (upper RNA layer, middle DNA layer, lower protein layer). Carefully transfer about 400μl of the upper aqueous phase to another RNAse free EP tube, add 1:1 volume of isopropanol, slowly invert up and down 8 times, and leave at room temperature for 10min.
[0074] Centrifuge at 4℃*12,000rpm*15min.
[0075] Gently pour off the supernatant, invert on a dust-free paper to absorb the residual liquid, add 1 ml of 75% alcohol (diluted with DEPC water), turn it upside down several times, centrifuge at 4℃*7500rpm*10min, and pour off the supernatant.
[0076] Repeat once, add 1 ml of 75% alcohol (diluted with DEPC water), invert several times, centrifuge at 4°C*7500rpm*10min, and discard the supernatant.
[0077] Centrifuge the EP tube that has been drained of liquid again at 7500rpm*1min, cover the 20μl pipette tip with a 10μl pipette tip, drain the remaining liquid (avoid draining the precipitate), and open the lid to dry at room temperature for 5min.
[0078] Add 15-20 μl of DEPC water to each well to dissolve RNA.
[0079] The OD value and RNA concentration of the obtained RNA were measured by Nanodrop, recorded on the wall of the corresponding EP tube and stored at -80℃ for future use;
[0080] 4. Cellular RNA Extraction
[0081] Precool a high-speed centrifuge to 4 °C.
[0082] Prepare 75% ethanol (1 volume of DEPC water + 3 volumes of analytical grade anhydrous ethanol) and place on ice.
[0083] After washing the cells three times with pre-cooled PBS, discard the PBS. Add 1 ml of Trizol to each well of the six-well plate, pipette until the cells fall off, and place on ice for 30 minutes.
[0084] The remaining steps are the same as above.
[0085] 5. Reverse transcription of extracted RNA into cDNA
[0086] Prepare the reaction mixture on ice throughout the process
[0087] The reaction system was 20 μl / well and the total RNA volume was 1 μg.
[0088] The reaction system is as follows: (TAKARA, RR036A kit)
[0089]
[0090] The reaction procedure for reverse transcription of RNA into cDNA is: 37℃*15min; 85℃*5sec; 4℃*∞.
[0091] 6. Real-time fluorescence quantitative PCR (qPCR)
[0092] The obtained cDNA was diluted 4-fold with DEPC water.
[0093] This part of the experiment was carried out using TAKARA's TB green real-time fluorescence quantitative PCR kit.
[0094] Mark the EP tubes according to the corresponding number of samples and the number of genes to be tested, prepare the following reaction system, mix the system well, and place it on ice.
[0095]
[0096]
[0097] According to the above system, duplicate wells are set for the test samples.
[0098] qPCR machine procedure:
[0099] Stage 1 (pre-denaturation): 95°C, 30 s;
[0100] Stage 2 (PCR reaction stage): 95°C, 5s; 60°C, 30s (fluorescence photography); 40 cycles in total.
[0101] Stage 3 (melting curve).
[0102] After the above steps are completed, the relative quantitative analysis results are calculated using 2-△△Ct). (△Ct = Ct value of target gene - Ct value of internal reference gene, △△Ct = △Ct value of experimental group - △Ct value of control group) (internal reference is GAPDH)
[0103] 7. Protein extraction from cells and mouse kidney tissue
[0104] Prepare total protein lysis buffer: mix RIPA lysis with 100x protease inhibitor and 100x phosphatase inhibitor.
[0105] Cell protein extraction: Add 100 μl of the mixture to each well of a six-well plate, scrape the cells evenly, and place on ice for 30 min.
[0106] Renal tissue protein extraction: Weigh the renal cortex, add the corresponding volume of the mixture and two grinding magnetic beads, grind the tissue using a tissue homogenizer at 60 Hz*20 s*2 times (until it is homogenized and no solid tissue is visible to the naked eye), and let it stand on ice for 30 min.
[0107] Centrifuge at 4°C*12,000rpm*15min and transfer the supernatant to a new EP tube.
[0108] 8. BCA protein assay
[0109] According to the Bio-Time BCA assay kit, the BCA standard was prepared to a final concentration of 0.5 mg / ml and stored at -20°C after aliquoting.
[0110] The cell protein stock solution was diluted 10 times with PBS, and the kidney tissue protein stock solution was diluted 30 times. After being fully mixed, the mixture was placed on ice.
[0111] In a 96-well ELISA plate, add the 0.5 mg / ml concentration standard bottle to the 96-well plate in the order of 0 μl, 1 μl, 2 μl, 4 μl, 8 μl, 12 μl, 16 μl, and 20 μl (set up double wells), and then add PBS to each well to a final volume of 20 μl. Add 20 μl of the sample to be tested to the remaining wells in turn.
[0112] At the same time, according to the number of samples to be measured, the A solution and the B solution of the BCA kit are mixed thoroughly at a volume ratio of 50:1. 200 μl of each well is added to the standard well and sample well, incubated at 37°C for 30 minutes, and the OD value is measured between 540-595 nm.
[0113] At this time, the concentrations of the standard substances were 0, 0.025, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 mg / ml per well, respectively. A standard curve was drawn according to the OD value and the concentration of the standard substance, and the measured concentration (μg / μl) and actual concentration of each sample were calculated.
[0114] Add 5× loading buffer to each sample according to its volume, mix well, heat at 100℃ for 10 min, and store at -80℃ for later use.
[0115] 9.Western blot
[0116] Use 1.5mm glass plate to prepare SDS gel. After assembling the glass plate, use anhydrous ethanol to check for leaks and then discard the anhydrous ethanol.
[0117] According to the molecular weight of the target protein, prepare about 7.5 ml of SDS polyacrylamide gel electrophoresis separation gel of different concentrations of 6%, 7.5%, 10%, 12.5%, and 15%, add it to the glass plate, seal it with anhydrous ethanol for about 30 minutes, and wait for the gel to solidify. Pour out the anhydrous ethanol and absorb the ethanol with dust-free paper.
[0118] Prepare 5% concentrated gel according to the following method, mix well and cover with separation gel, quickly insert into 15-hole or 10-hole comb, wait for 30 minutes before use.
[0119]
[0120] Sample loading and electrophoresis: Prepare the electrophoresis solution according to the following formula, pour the electrophoresis solution into the electrophoresis tank, and remove the comb. Load the samples in the order of protein marker and sample protein, with 20 μg of cell protein and 40 μg of tissue protein. After 30 minutes of constant voltage electrophoresis at 80V, switch to 120V constant voltage and continue electrophoresis until bromophenol blue reaches the bottom of the gel, then stop electrophoresis.
[0121] Transfer: Use a seesaw to separate the two glass plates and remove the concentrated gel. Cut a PVDF membrane, two transfer filter papers, and two transfer sponges of the same area as the separation gel. Use analytical grade methanol to fully activate the PVDF membrane, pour in the pre-cooled transfer solution, and perform western blot transfer in the order of the black side of the transfer clip, transfer sponge, transfer filter paper, gel, PVDF membrane, transfer filter paper, transfer sponge, and white side of the transfer clip (prevent bubbles from forming during the process). (Transfer conditions: constant current 300mA transfer 1KD / min, ice bath.)
[0122]
[0123] Blocking: 5% BSA blocking (5g BSA + 100ml 1XTBST solution), mix well. Block the transferred membrane at room temperature for 1 hour.
[0124] Place the membrane at the position indicated by the marker and cut the membrane to the appropriate size. Wash the membrane with 1x TBST for 5 min*3 times.
[0125] Primary antibody incubation: dilute the primary antibody with commercial antibody diluent or 5% BSA solution according to the recommended ratio in the antibody manual. Incubate with primary antibody at 4°C overnight.
[0126] Wash the membrane with 1x TBST for 5 min*3 times.
[0127] Secondary antibody incubation: According to the species of the primary antibody, incubate the PVDF membrane with Goat anti-Rabbit secondary antibody or Goat anti-Mouse secondary antibody (secondary antibody dilution ratio is 1:5000) at room temperature for 1 hour.
[0128] Wash the membrane with 1x TBST for 5 min*3 times.
[0129] Mix the A and B solutions of ECL luminescent solution in a ratio of 1:1; immediately cover the membrane in the ECL luminescent solution for 1 min, illuminate with a chemiluminescence instrument, and save the image.
[0130] 10. Detection of mouse blood Scr and urine ACR
[0131] Mouse blood Scr detection: Mouse blood Scr was detected according to the standard procedure of Crystal CC kit.
[0132] Mouse urine Cr detection: The absorbance level in random mouse urine was detected according to the standard procedure of the Exocell kit. The appropriate dilution factor of the urine specimen was obtained in the preliminary experiment. The absorbance of each sample was calculated according to the formula: Adelta = Aalkaline picrate-Aalkaline picrate+acid. The least squares regression equation was determined using the Adelta / creatinine concentration ratio of each standard. The calculated urine Cr value of each mouse was calculated using this equation and multiplied by the dilution factor to obtain the actual value of urine Cr.
[0133] Mouse urine alb detection: The absorbance value of urine alb in random mouse urine was detected according to the standard process of the Exocell kit. The appropriate dilution multiple of the urine specimen was obtained in the preliminary experiment. The concentration and absorbance of the standard were analyzed by semi-logarithmic analysis to obtain the following equation log10 MSA = mA450 + b. The calculated value of urine alb for each mouse was calculated by this equation and multiplied by the dilution multiple to obtain the actual value of urine alb.
[0134] Urine ACR value = urine alb / urine Cr (unit conversion).
[0135] 11. Paraffin Embedding of Mouse Tissue
[0136] The kidneys were fixed in 4% paraformaldehyde for 24 hours and then rinsed under running water for 2 hours.
[0137] Dehydration: The tissue was immersed in 70% ethanol overnight, immersed in two 80% ethanol concentrations for 30 min, immersed in two 95% ethanol concentrations for 30 min, and immersed in 100% anhydrous ethanol for 30 min.
[0138] Transparency: Immerse in xylene twice, for 30 min each.
[0139] Wax dipping: In a 60°C oven, the kidney tissue was sequentially immersed in two batches of melted liquid paraffin for 2 h each.
[0140] Embedded sections: trim the section of the solidified paraffin block containing the tissue, cut it into 3 μm thick sections, spread the sections in a 40°C water bath, and bake the sections on anti-shedding slides at 60°C for 6 hours before use.
[0141] 12. H&E staining
[0142] Dewaxing: Place 3 μm mouse kidney tissue paraffin sections in a 70°C oven for 1 hour. Then dewax the sections in xylene I and xylene II for 20 minutes each.
[0143] Hydration: Place the sections in anhydrous ethanol I and anhydrous ethanol II for 5 minutes each, then place them in 95% ethanol and 80% ethanol for 10 minutes each, and then rinse them in tap water for 10 minutes.
[0144] Staining: Slices were stained with Harris hematoxylin for 5 minutes, then rinsed with running water for 5 minutes. Then the slices were soaked in 1% hydrochloric acid alcohol (absolute ethanol: distilled water: concentrated hydrochloric acid volume ratio = 70:30:1), rinsed with tap water for 10 minutes to turn blue, washed once with double distilled water, and quickly soaked in 95% ethanol.
[0145] Soak the sections in eosin solution for 30 seconds, 95% ethanol I and 95% ethanol II for 1 minute each, then soak in anhydrous ethanol I and anhydrous ethanol II for 2 minutes each. Soak in fresh xylene I and xylene II for 2 minutes each, and drain slightly. After sealing with neutral resin (fresh xylene diluted appropriately), observe under a microscope.
[0146] 13.PAS staining
[0147] 3 μm tissue sections were dewaxed and hydrated.
[0148] Staining: Soak the slices in 1% periodic acid solution for 15 minutes, wash in dd water 3 times*5 minutes. Stain the slices in Schiff's stain for 10 minutes, rinse in running water for 5 minutes, and the tissue will turn pink under the naked eye.
[0149] The nuclei were stained with hematoxylin for 1 min and rinsed with running water for 5 min.
[0150] Digest with 1% hydrochloric acid alcohol for about 5 seconds and rinse with running water for 5 minutes.
[0151] Soak in 95% ethanol I and 95% ethanol II for 1 min each, then soak in anhydrous ethanol I and anhydrous ethanol II for 2 min each. Soak in fresh xylene I and xylene II for 2 min each, drain slightly. Seal the slide with neutral resin (appropriately diluted with fresh xylene) and observe under a microscope.
[0152] 14. Immunohistochemistry of Mouse Paraffin Sections
[0153] Paraffin tissue sections 3 μm.
[0154] Dewaxing and hydration: bake the slides at 70℃ for 1h; dewax with xylene for 45min*2 times; hydrate with gradient alcohol: 100%*1 time, 90%*1 time, 80%*1 time, 70%*1 time, 5min each time; wash with dd water 3 times*5min.
[0155] Antigen retrieval: Place the slide in 10mmol / L pH=6.0 citrate buffer, heat in boiling water for 20min, open the lid and cool to room temperature; PBS 3 times*5min.
[0156] Block endogenous peroxidase: wipe off the water droplets, add 3% hydrogen peroxide, protect from light for 15-30 minutes; wash with PBS 3 times * 5 minutes.
[0157] Circle tissue and seal: circle the tissue with a brush; incubate with 1% BSA+PBS or non-immune goat serum at room temperature for 1 hour.
[0158] Incubate with primary antibody: shake off the blocking serum, add primary antibody diluted with 1% BSA (pP38 antibody concentration 1:400), incubate overnight at 4°C (add a small amount of water in the wet box to prevent antibody evaporation); wash with PBS 3 times * 5 min.
[0159] Incubate with secondary antibody: After discarding PBS, add HRP-labeled secondary antibody of the same species as the primary antibody (diluted at 1:500) to the circle, cover the tissue with secondary antibody, and incubate at room temperature for 30 minutes. Wash with PBS 3 times*5 minutes.
[0160] DAB color development: wipe off the water droplets; mix DAB A solution and B solution at a concentration of 1:1; control the color development time under a microscope. When the color turns brown, stop color development and rinse under running water for 15 minutes.
[0161] Staining cell nuclei: wipe off water droplets, counterstain with Harris hematoxylin for about 1 minute, differentiate with 1% hydrochloric acid alcohol for a few seconds, rinse with tap water, turn blue with ammonia water, and rinse with running water away from the tissue for 15 minutes.
[0162] Dehydration and transparency with gradient alcohol: 70%, 80%, 90%, 100% alcohol gradient dehydration, transparency with pure xylene. After slightly drying, seal with neutral gum.
[0163] 15. Plasmid transformation and extraction
[0164] Prepare liquid LB medium: 5 g yeast powder + 10 g peptone + 10 g sodium chloride, add water to 1 L, sterilize by high pressure, and store at 4°.
[0165] Prepare solid LB medium: 0.5g yeast powder + 1g peptone + 1g sodium chloride + 1g agar powder, add water to 100ml. After cooling, add antibiotics at a ratio of 1:1000 and pour into a 10cm plate. (The prepared LB and plates should be stored at 4°, and the plates should be placed upside down).
[0166] Plasmid transformation: Pipette a small amount of plasmid into the EP tube containing 100 μl DH5α competent cells, flick to mix, and place on ice for 10 minutes.
[0167] Heat activation: Place the EP tube in a 42°C water bath for 1 minute, then immediately place it back on ice. At the same time, prepare liquid LB medium and LB plates containing the corresponding resistance of the plasmid.
[0168] Activation: Operate in a biosafety cabinet, add 700 μl of resistance-free LB (recovered at room temperature) to each EP tube, mix well by inverting several times, and activate in a shaker at 37°C and 220 rpm for 1 hour.
[0169] Centrifugal concentration: Take out the activated EP tube and centrifuge at 4000rpm for 3min.
[0170] Mixing: Take it to the biosafety cabinet, aspirate the supernatant until there is about 50-70ul left, and mix it by pipetting several times.
[0171] Plate coating: Plate the bacterial solution onto the corresponding drug-resistant plate, invert, and incubate at 37°C overnight.
[0172] Shake the bacteria: Select a single clone and add it to 100 ml LB medium containing antibiotics, and shake it at 37°C and 220 rpm overnight.
[0173] Centrifugation: 100 ml of the shaken bacterial solution was centrifuged at 8000 rpm for 5 min, the supernatant was discarded, and the precipitate was retained.
[0174] Plasmid extraction:
[0175] Add 6 ml of P1 to the pellet and resuspend it completely.
[0176] Add 6 ml of P2 and mix gently until the liquid turns blue.
[0177] Add 6 ml of S3 and mix gently. You can see obvious flocculent precipitation. Pour all the liquid into the syringe filter in the kit, then let it stand for 10 minutes and filter it into a new 50 ml cannon tube under pressure.
[0178] Add 3 ml of binding buffer to the cannon tube and mix well. Add an extension tube to the 1 ml column, add all the liquid to the column with the extension tube, connect a vacuum aspirator under the column to vacuum, and bind the plasmid to the column.
[0179] Endotoxin removal: Add 700ul of ETR once, centrifuge at 15000rpm*30s*1 time.
[0180] Washing: Add 700ul of PE (wash once), centrifuge at 15000rpm*30s, open the lid and let dry for about 1min, and discard the liquid in the collection tube.
[0181] Centrifuge again at 15000rpm*1min and dry for 1min.
[0182] Add 150 μl RNA-free water, let stand for 20 min, centrifuge at 15000 rpm*1 min, and collect into a sterile 1.5 ml centrifuge tube.
[0183] The plasmid concentration was measured by nanodrop instrument and diluted to 1 μg / μl with appropriate amount of RNA-free water.
[0184] 16. Glomerular Extraction and mRNA Sequencing
[0185] A HBSS equilibrated solution containing Dynabeads M-450 (Invitrogen, Carlsbad, CA) magnetic beads was prepared.
[0186] After anesthetizing the mice, a balanced solution containing magnetic beads was perfused through the systemic circulation. At this time, it can be seen that the bilateral kidneys of the mice turned reddish brown.
[0187] The kidneys were removed and minced on ice, and then digested with 1 mg / mL Collagen A and 100 U / mL DNase I at 37°C for 30 min.
[0188] The cells were then filtered through a 100-μm Falcon cell strainer (BD Falcon, Bedford, MA), gently rinsed with HBSS equilibration solution, and the filtrate was collected into a new centrifuge tube.
[0189] Repeat once, filter using a 100-μm Falcon cell strainer (BD Falcon, Bedford, MA), gently rinse with HBSS equilibration solution, and collect the filtrate into a new centrifuge tube.
[0190] The collected filtrate was centrifuged at 200 g for 5 min, the pellet (containing glomeruli) was retained, and the supernatant was discarded.
[0191] Add new HBSS balance solution and resuspend. Place the EP tube on the magnetic rack and let it stand for about 2 minutes. You can see that the precipitate is adsorbed on the EP tube near the magnetic rack surface. Gently remove the supernatant. Repeat this step 2 times. For the last time, aspirate a little supernatant for microscopic examination.
[0192] Place it on the magnetic rack again, aspirate the supernatant, and centrifuge at 500g for 2 minutes to allow all glomeruli to settle to the bottom of the EP tube. Store the sample at -80℃ for subsequent RNA extraction.
[0193] This time, we extracted 9 mutant and 9 wild-type mice, combined every three mice of the same genotype into one sample, and performed mRNAseq sequencing analysis.
[0194] 2. Experimental Results
[0195] The present invention first discovered the pathogenic COL4A3p.G801R point mutation site in a clinical hereditary nephropathy family through whole exome sequencing. Further, by comparing the mouse and human COL4A3 gene sequences, the present invention found that the 799th amino acid of the mouse COL4A3 gene was homologous to the 801 site of the human COL4A3 gene, and constructed a COL4A3p.G799R point mutation mouse ( Figure 1-7 , Table 1-4). The present invention detected the renal function and urine albumin-creatinine ratio (ACR) of homozygous mice at 8, 24, and 40 weeks of age. Compared with wild-type mice, the ACR level of mutant mice at 24 weeks gradually increased and reached a significant level ( Figure 8 A), body weight was reduced compared with the wild-type group ( Figure 8 C). Serum creatinine (Scr) levels also showed a similar upward trend, with a significant increase observed in mutant mice at 40 weeks ( Figure 8 B) In terms of kidney tissue damage assessment, foot processes were found to disappear in mutant mice at 8 weeks of age ( Fig. 9 C, 9E), the mutant mice showed irregular thinning and thickening of GBM at 24 weeks of age ( Fig. 9 C, 9D), glomerular capillary loop contraction and collapse ( Fig. 9A, 9B). This is similar to the progression of renal disease in patients with IV collagen α3 chain (COL4A3) mutations, confirming that the clinical phenotype and pathological results of this model mouse can effectively simulate the natural progression of COL4A3 mutation-related clinical diseases and can be used for related clinical research and drug development.
[0196] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. A method for preparing a COL4A3 p.G799R point mutation animal model, It is characterized in that The following steps are involved: Step 1: Determine that the mutation site of the mouse COL4A3 gene is COL4A3 p.G799R; obtain Cas9 mRNA and gRNA by in vitro transcription, and the sequence of gRNA is shown in SEQ ID No.1, SEQ ID No.2 or SEQ ID No.3; construct a homologous recombination vector donor vector by In-Fusion cloning; microinject Cas9 mRNA, gRNA and donor vector into fertilized eggs of C57BL / 6J mice to obtain F0 generation mice; Step 2: Mouse genotype identification and model The injected fertilized eggs were transplanted into pseudo-pregnant female mice, and the mice born around 20 days later were F0 generation mice. The genotypes were identified by PCR amplification and sequencing to obtain the target COL4A3 p.G799R point mutation mice. The COL4A3 p.G799R point mutation mice with C57BL / 6 background were hybridized into nephropathy-susceptible mice with 129S2 / Sv background. Step 4: Obtaining F1 generation mice and identifying their genotypes The F0 positive mice were mated with wild-type C57BL / 6J mice to obtain the F1 mice, and their genotypes were identified by PCR and sequencing; Step 5: Screen the F2 progeny and obtain the homozygous mutant mice therein, which are the COL4A3 p.G799R point mutation animal model to be prepared in the present invention.
2. The method for preparing the COL4A3 p.G799R point mutation animal model according to claim 1, It is characterized in that The donor vector sequence is shown in SEQ ID NO.
4.
3. The method for preparing the COL4A3 p.G799R point mutation animal model according to claim 1, It is characterized in that The PCR primers used for genotyping COL4A3 p.G799R point mutation mice are shown as SEQ ID NO.5 and SEQ ID NO.
6.
4. The method for preparing a COL4A3 p.G799R point mutation animal model according to claim 1, It is characterized in that The PCR reaction system for genotyping COL4A3 p.G799R point mutation mice is as follows:
5. The method for preparing the COL4A3 p.G799R point mutation animal model according to claim 1, It is characterized in that The PCR reaction procedure for genotyping mice with the COL4A3 p.G799R point mutation is as follows: 。 6. Use of the COL4A3 p.G799R point mutation animal model constructed by the method for preparing the COL4A3 p.G799R point mutation animal model according to any one of claims 1 to 5 in screening therapeutic drugs for hereditary chronic kidney disease.
7. Use of the COL4A3 p.G799R point mutation animal model constructed by the method for preparing the COL4A3 p.G799R point mutation animal model according to any one of claims 1 to 5 in studying the pathogenesis of hereditary chronic kidney disease.
